查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822371

2032 年Fluoroquinolones市場預測：按類型、頻譜、給藥途徑、代數、適應症和地區進行的全球分析

Fluoroquinolones Market Forecasts to 2032 - Global Analysis By Type (Oral Fluoroquinolones, Injectable Fluoroquinolones, and Other Types), Spectrum, Route of Administration, Generation, Indication and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球Fluoroquinolones市場預計在 2025 年達到 49.5 億美元，到 2032 年將達到 80.5 億美元，預測期內的複合年成長率為 7.2%。

Fluoroquinolones藥物是一類合成抗生素，以其廣譜抗細菌感染活性而聞名。其主要作用是抑制DNA旋轉酶和拓樸異構酶IV，這兩種酵素是細菌DNA加工所必需的。它們常用於治療肺部、泌尿道、消化器官系統和皮膚感染疾病。雖然Fluoroquinolones口服有效且方便，但由於存在相關風險，包括斷裂、神經系統併發症以及細菌抗藥性的產生，因此必須謹慎使用。

根據世界衛生組織（WHO）2023年的報告，東南亞是全球結核病新發病例最多的地區，佔全球結核病新病例的45.0%，約佔全球結核病新病例的87.0%。

細菌感染增加

隨著診斷能力的提升和對抗菌素抗藥性認知的不斷加深，醫療保健提供者正優先考慮使用頻譜藥物進行快速介入。Fluoroquinolones因其對革蘭氏陰性和革蘭氏陽性病原體的有效性，在住院和門診環境中的使用日益增多。分子診斷技術的進步使得病原體識別更加快速，從而支持有針對性的抗生素使用。人口老化和免疫力缺乏患者數量的增加進一步推高了感染率和抗生素消費量。日益加重的臨床負擔正在推動對下一代Fluoroquinolones及其給藥系統的持續投資。

嚴重的副作用和安全問題

美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構發布了黑框警告和使用限制，影響了醫生的處方行為。藥物安全檢測平台和人工智慧驅動的不利事件追蹤技術正在幫助更密切地監測藥物的安全性。關於長期毒性和微生物組破壞的新研究呼籲更謹慎地使用藥物。這些擔憂正在減緩市場擴張，尤其是在藥品核准框架嚴格的地區。因此，製造商正在投資研發配方改良的藥物和風險緩解策略，以恢復臨床可信度。

門診抗生素治療需求不斷增加

門診治療的轉變加速了對便利、廣效口服Fluoroquinolones的需求。遠端醫療平台和遠距離診斷正在加快處方流程，特別是對於併發症感染疾病。緩釋性和患者友善給藥方案的創新正在提高依從性和治療效果。醫療保健系統越來越傾向於具有成本效益的門診治療，以減輕醫院負擔並改善資源分配。在新興市場，基層醫療和數位醫療工具的普及正在擴大抗生素的覆蓋範圍，使其擴展到都市區以外。這一趨勢為客製化包裝、網路藥局分銷和行動醫療整合創造了新的機會。

學名藥競爭加劇

專利到期正推動低成本替代品的激增，尤其是在Ciprofloxacin和levofloxacin等高用量領域。監管機構對學名藥核准的支持和簡化的生物等效性試驗正在加速市場准入。數位採購平台和醫院集中競標鼓勵學名藥而非品牌藥的大量採購。為了保持競爭力，原廠藥廠正專注於差異化配方、聯合治療和生命週期管理策略。然而，由於缺乏明顯的臨床優勢，品牌Fluoroquinolones在成熟市場和新興市場都面臨失敗的風險。

COVID-19的影響

新冠疫情擾亂了抗生素供應鏈，改變了處方模式，尤其是在尖峰時段。Fluoroquinolones並非第一線抗病毒藥物，而是用於治療新冠患者的繼發性細菌感染疾病。封鎖和生產延誤導致了抗生素暫時短缺，迫使各國政府重新評估抗生素庫存和分配通訊協定。監管機構推出了緊急使用途徑，並加快了基本抗生素的核准。疫情後的策略如今強調供應鏈的韌性、抗菌藥物管理以及人工智慧在感染疾病監測中的整合。

口服Fluoroquinolones預計將在預測期內佔據最大的市場佔有率

由於口服Fluoroquinolones藥物廣泛用於治療社區性感染症，預計該類藥物將在預測期內佔據最大的市場佔有率。口服Fluoroquinolones生物利用度高、給藥方便、療效範圍廣，是門診治療的理想選擇。片劑包覆和控制釋放機制的創新提高了患者的依從性，並最大限度地減少了胃腸道副作用。醫院和診所擴大採用口服療法，以減少住院時間和醫療成本。網路藥局平台和行動醫療應用程式的興起進一步促進了口服抗生素的可及性。在對分散治療的需求不斷成長的背景下，口服Fluoroquinolones在銷售量和價值方面繼續保持領先地位。

預計呼吸道感染疾病領域在預測期內將達到最高複合年成長率

預計呼吸道感染疾病領域將在預測期內達到最高成長率。Fluoroquinolones因其強大的抗呼吸道病原體活性，常用於治療支氣管炎、肺炎和鼻竇炎。就地檢驗和人工智慧輔助放射學的進步使得診斷速度更快、治療更有針對性。季節性流行病和空氣污染相關併發症導致都市區抗生素處方量增加。醫療保健提供者正在採用Fluoroquinolones藥物治療第一線治療無效的抗藥性菌株。該領域也受益於正在探索新的組合和可吸入製劑以增強肺部輸送的臨床試驗。

佔比最高的地區：

由於感染率高且醫療基礎設施不斷擴張，預計亞太地區將在預測期內佔據最大的市場佔有率。由於人口稠密和衛生條件有限，中國、印度和印尼等國家的抗生素消費量正在上升。政府正在採取措施推動本地製造和學名藥生產，以滿足日益成長的需求。該地區還正在採用數位健康平台和行動診斷技術，以改善農村地區Fluoroquinolones的可及性。全球製藥公司與本地經銷商之間的策略合作夥伴關係正在推動供應鏈效率的提升。

複合年成長率最高的地區：

在先進的醫療體系和強勁的研發投入的支持下，北美地區預計將在預測期內呈現最高的複合年成長率。美國和加拿大在抗生素管理、精準診斷和人工智慧處方分析方面發揮主導作用。監管機構正在簡化新型Fluoroquinolones衍生物和聯合治療的核准途徑。醫院正在整合電子健康記錄和預測演算法，以最佳化抗生素使用並降低抗藥性。該地區也受益於強大的報銷框架和廣泛採用的門診護理模式。隨著藥物傳遞和製劑創新的加速，北美將繼續塑造Fluoroquinolones的未來。

免費客製化服務

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球Fluoroquinolones市場類型

  • 口服Fluoroquinolones
  • 注射用Fluoroquinolones藥物
  • 其他類型

6. 全球Fluoroquinolones藥物市場（頻譜）

  • 窄頻頻譜
  • 頻譜

7. 全球Fluoroquinolones市場（依給藥途徑）

  • 口服
  • 眼藥水
  • 靜脈
  • 滴鼻劑

8. 全球Fluoroquinolones市場（依代數）

  • 第一代
  • 第二代
  • 第三代
  • 第四代

9. 全球Fluoroquinolones市場（按適應症）

  • 呼吸道感染疾病
  • 眼部感染疾病
  • 尿道感染
  • 胃腸道感染疾病
  • 性行為感染傳染病
  • 皮膚和軟組織感染疾病
  • 其他適應症

10. 全球Fluoroquinolones藥物市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 12 章：公司概況

  • Bayer AG
  • Aurobindo Pharma
  • Pfizer Inc.
  • Dr. Reddy's Laboratories
  • Novartis AG
  • Glenmark Pharmaceuticals
  • Sanofi
  • Mylan NV
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC31125

According to Stratistics MRC, the Global Fluoroquinolones Market is accounted for $4.95 billion in 2025 and is expected to reach $8.05 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Fluoroquinolones represent a group of synthetic antibiotics known for their broad activity against bacterial infections. Their primary action involves blocking DNA gyrase and topoisomerase IV, enzymes necessary for bacterial DNA processes. They are often prescribed for infections of the lungs, urinary tract, digestive system, and skin. While effective and convenient for oral administration, fluoroquinolones must be used carefully because of associated risks such as tendon rupture, nerve complications, and antibiotic resistance development.

According to the World Health Organization report in 2023, the highest number of new tuberculosis (TB) cases were reported in the Southeast Asia region, accounting for 45.0% of total cases, and amongst these, approximately 87.0% of new TB cases.

Market Dynamics:

Driver:

Rising prevalence of bacterial infections

As diagnostic capabilities improve and awareness of antimicrobial resistance grows, healthcare providers are prioritizing broad-spectrum agents for rapid intervention. Fluoroquinolones are increasingly used in both inpatient and outpatient settings due to their efficacy against gram-negative and gram-positive pathogens. Technological advancements in molecular diagnostics are enabling faster pathogen identification, supporting targeted antibiotic use. The aging population and rise in immunocompromised patients are further contributing to infection rates and antibiotic consumption. This growing clinical burden is driving sustained investment in next-generation fluoroquinolone formulations and delivery systems.

Restraint:

Severe side effects and safety concerns

Regulatory agencies like the FDA and EMA have issued black-box warnings and usage restrictions, impacting physician prescribing behavior. The integration of pharmacovigilance platforms and AI-driven adverse event tracking is helping monitor safety profiles more rigorously. Emerging research on long-term toxicity and microbiome disruption is prompting calls for more selective use. These concerns are slowing market expansion, especially in regions with stringent drug approval frameworks. As a result, manufacturers are investing in reformulated compounds and risk-mitigation strategies to restore clinical confidence.

Opportunity:

Rising demand for outpatient antibiotic treatments

The shift toward outpatient care is accelerating demand for oral fluoroquinolones that offer convenience and broad-spectrum coverage. Telemedicine platforms and remote diagnostics are enabling faster prescription workflows, especially for uncomplicated infections. Innovations in extended-release formulations and patient-friendly dosing regimens are improving adherence and therapeutic outcomes. Healthcare systems are increasingly favouring cost-effective outpatient treatments to reduce hospital burden and improve resource allocation. In emerging markets, rising access to primary care and digital health tools is expanding antibiotic reach beyond urban centres. This trend is opening new opportunities for tailored packaging, e-pharmacy distribution, and mobile health integration.

Threat:

Increasing generic competition

Patent expirations have led to a proliferation of low-cost alternatives, particularly in high-volume segments like ciprofloxacin and levofloxacin. Regulatory support for generic approvals and streamlined bioequivalence testing is accelerating market entry. Digital procurement platforms and centralized hospital tenders are favouring bulk purchases of generics over branded options. To remain competitive, originator companies are focusing on differentiated formulations, combination therapies, and lifecycle management strategies. However, without clear clinical superiority, branded fluoroquinolones risk losing ground in both mature and emerging markets.

Covid-19 Impact

The COVID-19 pandemic disrupted antibiotic supply chains and altered prescribing patterns, especially during peak hospitalization periods. While fluoroquinolones were not frontline antivirals, they were used to manage secondary bacterial infections in COVID patients. Lockdowns and manufacturing delays led to temporary shortages, prompting governments to reassess antibiotic stockpiling and distribution protocols. Regulatory bodies introduced emergency use pathways and fast-track approvals for essential antimicrobials. Post-pandemic strategies now emphasize supply chain resilience, antimicrobial stewardship, and integration of AI in infection surveillance.

The oral fluoroquinolones segment is expected to be the largest during the forecast period

The oral fluoroquinolones segment is expected to account for the largest market share during the forecast period, due to its widespread use in treating community-acquired infections. These formulations offer high bioavailability, ease of administration, and broad-spectrum efficacy, making them ideal for outpatient care. Technological innovations in tablet coatings and controlled-release mechanisms are enhancing patient compliance and minimizing gastrointestinal side effects. Hospitals and clinics are increasingly adopting oral regimens to reduce inpatient stays and healthcare costs. The rise of e-pharmacy platforms and mobile health apps is further boosting access to oral antibiotics. As demand for decentralized treatment grows, oral fluoroquinolones continue to lead in both volume and revenue.

The respiratory tract infections segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the respiratory tract infections segment is predicted to witness the highest growth rate, fuelled by rising incidence and diagnostic improvements. Fluoroquinolones are often prescribed for bronchitis, pneumonia, and sinusitis due to their potent action against respiratory pathogens. Advances in point-of-care testing and AI-assisted radiology are enabling quicker diagnosis and targeted therapy. Seasonal outbreaks and air pollution-related complications are increasing antibiotic prescriptions in urban centers. Healthcare providers are adopting fluoroquinolones for resistant strains where first-line treatments fail. This segment is also benefiting from clinical trials exploring novel combinations and inhalable formulations for enhanced pulmonary delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by high infection rates and expanding healthcare infrastructure. Countries like China, India, and Indonesia are witnessing increased antibiotic consumption due to population density and limited sanitation. Government initiatives are promoting local manufacturing and generic production to meet rising demand. The region is also embracing digital health platforms and mobile diagnostics to improve rural access to fluoroquinolones. Strategic collaborations between global pharma firms and regional distributors are enhancing supply chain efficiency.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, supported by advanced healthcare systems and robust R&D investment. The U.S. and Canada are leading in antimicrobial stewardship, precision diagnostics, and AI-driven prescription analytics. Regulatory agencies are streamlining approval pathways for novel fluoroquinolone derivatives and combination therapies. Hospitals are integrating electronic health records and predictive algorithms to optimize antibiotic use and reduce resistance. The region also benefits from strong reimbursement frameworks and widespread adoption of outpatient care models. As innovation in drug delivery and formulation accelerates, North America continues to shape the future of fluoroquinolone therapeutics.

Key players in the market

Some of the key players profiled in the Fluoroquinolones Market include Bayer AG, Aurobindo Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Novartis AG, Glenmark Pharmaceuticals, Sanofi, Mylan N.V., GlaxoSmithKline plc, Cipla Ltd., Johnson & Johnson, Lupin Pharmaceuticals, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Key Developments:

In September 2025, Bayer announced the launch of Bayer Co.Lab AdVenture, a new platform for its Bayer Co.Lab global life sciences incubator network, which aims to connect venture capital partners globally. Bayer Co.Lab AdVenture bridges tenants of high-potential biotech startups with leading venture capital firms, accelerating access to global financing and investment networks, thereby advancing the translation of early-stage ideas into impactful global solutions.

In September 2025, Pfizer Inc. and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY(R) (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19.

Types Covered:

  • Oral Fluoroquinolones
  • Injectable Fluoroquinolones
  • Other Types

Spectrums Covered:

  • Narrow-Spectrum
  • Broad-Spectrum

Route of Administrations Covered:

  • Oral
  • Ophthalmic
  • Intravenous
  • Otic

Generations Covered:

  • First Generation
  • Second Generation
  • Third Generation
  • Fourth Generation

Indications Covered:

  • Respiratory Tract Infections
  • Ophthalmic Infections
  • Urinary Tract Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Diseases
  • Skin and Soft Tissue Infections
  • Other Indications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fluoroquinolones Market, By Type

  • 5.1 Introduction
  • 5.2 Oral Fluoroquinolones
  • 5.3 Injectable Fluoroquinolones
  • 5.4 Other Types

6 Global Fluoroquinolones Market, By Spectrum

  • 6.1 Introduction
  • 6.2 Narrow-Spectrum
  • 6.3 Broad-Spectrum

7 Global Fluoroquinolones Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Ophthalmic
  • 7.4 Intravenous
  • 7.5 Otic

8 Global Fluoroquinolones Market, By Generation

  • 8.1 Introduction
  • 8.2 First Generation
  • 8.3 Second Generation
  • 8.4 Third Generation
  • 8.5 Fourth Generation

9 Global Fluoroquinolones Market, By Indication

  • 9.1 Introduction
  • 9.2 Respiratory Tract Infections
  • 9.3 Ophthalmic Infections
  • 9.4 Urinary Tract Infections
  • 9.5 Gastrointestinal Infections
  • 9.6 Sexually Transmitted Diseases
  • 9.7 Skin and Soft Tissue Infections
  • 9.8 Other Indications

10 Global Fluoroquinolones Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer AG
  • 12.2 Aurobindo Pharma
  • 12.3 Pfizer Inc.
  • 12.4 Dr. Reddy's Laboratories
  • 12.5 Novartis AG
  • 12.6 Glenmark Pharmaceuticals
  • 12.7 Sanofi
  • 12.8 Mylan N.V.
  • 12.9 GlaxoSmithKline plc
  • 12.10 Cipla Ltd.
  • 12.11 Johnson & Johnson
  • 12.12 Lupin Pharmaceuticals
  • 12.13 Merck & Co., Inc.
  • 12.14 Sun Pharmaceutical Industries Ltd.
  • 12.15 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Fluoroquinolones Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Fluoroquinolones Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Fluoroquinolones Market Outlook, By Oral Fluoroquinolones (2024-2032) ($MN)
  • Table 4 Global Fluoroquinolones Market Outlook, By Injectable Fluoroquinolones (2024-2032) ($MN)
  • Table 5 Global Fluoroquinolones Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 6 Global Fluoroquinolones Market Outlook, By Spectrum (2024-2032) ($MN)
  • Table 7 Global Fluoroquinolones Market Outlook, By Narrow-Spectrum (2024-2032) ($MN)
  • Table 8 Global Fluoroquinolones Market Outlook, By Broad-Spectrum (2024-2032) ($MN)
  • Table 9 Global Fluoroquinolones Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 10 Global Fluoroquinolones Market Outlook, By Oral (2024-2032) ($MN)
  • Table 11 Global Fluoroquinolones Market Outlook, By Ophthalmic (2024-2032) ($MN)
  • Table 12 Global Fluoroquinolones Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 13 Global Fluoroquinolones Market Outlook, By Otic (2024-2032) ($MN)
  • Table 14 Global Fluoroquinolones Market Outlook, By Generation (2024-2032) ($MN)
  • Table 15 Global Fluoroquinolones Market Outlook, By First Generation (2024-2032) ($MN)
  • Table 16 Global Fluoroquinolones Market Outlook, By Second Generation (2024-2032) ($MN)
  • Table 17 Global Fluoroquinolones Market Outlook, By Third Generation (2024-2032) ($MN)
  • Table 18 Global Fluoroquinolones Market Outlook, By Fourth Generation (2024-2032) ($MN)
  • Table 19 Global Fluoroquinolones Market Outlook, By Indication (2024-2032) ($MN)
  • Table 20 Global Fluoroquinolones Market Outlook, By Respiratory Tract Infections (2024-2032) ($MN)
  • Table 21 Global Fluoroquinolones Market Outlook, By Ophthalmic Infections (2024-2032) ($MN)
  • Table 22 Global Fluoroquinolones Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
  • Table 23 Global Fluoroquinolones Market Outlook, By Gastrointestinal Infections (2024-2032) ($MN)
  • Table 24 Global Fluoroquinolones Market Outlook, By Sexually Transmitted Diseases (2024-2032) ($MN)
  • Table 25 Global Fluoroquinolones Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
  • Table 26 Global Fluoroquinolones Market Outlook, By Other Indications (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.